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afetyThe World Health Organization (WHO) inﬂuenza vaccine pol-
cy recommendations aim to protect vulnerable high-risk groups
rom severe disease. In a 2012 update of its inﬂuenza vaccine posi-
ion, WHO  recommends that countries considering the initiation
r expansion of programmes for seasonal inﬂuenza vaccination
hould prioritize pregnant women over other high risk groups
young children, the elderly, persons with certain chronic illnesses,
nd health care workers) [1]. The recommendation was  based
n numerous factors, including inﬂuenza disease risk in pregnant
omen and among their young children in the ﬁrst months after
irth, vaccine safety and effectiveness, as well the programmatic
pportunities to reach this population in low- and middle-income
ountries. This review describes the advancements made in the
eld of maternal inﬂuenza immunization since the 2012 WHO  pol-
cy recommendation, as well as the evidence gaps that remain. We
ocus on the evidence needs to review maternal inﬂuenza immu-
ization in the poorest countries—many of which have not yet
ntroduced inﬂuenza vaccine programs.
In 2013, GAVI, the Vaccine Alliance reviewed maternal inﬂuenza
mmunization for possible inclusion in its vaccine investment port-
olio for low-income countries. While GAVI opted not to invest
n the strategy, its review was generally positive. GAVI vac-
ine program impact models estimated that maternal inﬂuenza
mmunization could avert around 45 deaths per 100,000 per-
ons vaccinated in GAVI-eligible countries, similar to the expected
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uimpact of rubella and cholera immunization strategies [2]. If vac-
cine exposure decreased preterm births, the estimated impact of
the program would be much greater [2]. GAVI noted that the mod-
els were based on uncertain mortality and vaccine effectiveness
data [2]. Its review also identiﬁed other obstacles to a maternal
inﬂuenza immunization strategy including decreased awareness of
severe inﬂuenza disease, as well as a need for strengthening pol-
icy, regulatory, implementation, and monitoring processes in many
low-resource settings to ensure effective vaccine demand, supply,
and program sustainability [2].
A comprehensive assessment of the inﬂuenza disease burden is
available from a systematic review and meta-analysis of inﬂuenza-
associated acute lower respiratory infections in children <5 years
from 43 studies worldwide [3]. The authors estimated that in
2008 there were 28,000–111,500 deaths in children <5 years of
inﬂuenza-associated acute lower respiratory infections and that
99% of these deaths occurred in developing countries [3]. The
study did not determine mortality estimates for the subgroup <6
months, the age that would beneﬁt from maternal immunization.
The Institute for Health Metrics and Evaluation (IHME) estimated
that globally 1.7% of all deaths under ﬁve years of age are caused by
inﬂuenza (about 15,100 total deaths), although given the limited
published data available for children <6 months, the robustness
of IHME estimates are unclear [4]. Finally, the Pneumonia Etiology
Research for Child Health (PERCH) Project, a multi-country study of
children <5 years, has published pilot data suggesting that inﬂuenza
is not a major contributor to pneumonia [5,6]. The ﬁnal PERCH
study reports are expected soon [7]. More efforts are needed to col-
lect robust data on severe inﬂuenza disease in children <6 months,
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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articularly in low-income settings, and to reconcile discordant
ndings of different studies of inﬂuenza disease burden.
There are limited data on the incidence of severe inﬂuenza dis-
ase among pregnant women globally [8]. A systematic review and
eta-analysis of comparative observational studies of pregnant
nd non-pregnant women with inﬂuenza and severe outcomes
as recently published [9]. This review found only one study
f pregnancy risk associated with seasonal inﬂuenza virus infec-
ion, while the remaining relevant studies were from the 2009
nﬂuenza A (H1N1) pandemic [9]. As the rates of severe inﬂuenza
utcomes during the 2009 H1N1 pandemic increased in young
dults [10], further research is needed to conﬁrm whether severe
utcomes in pregnant women are also associated with seasonal
nﬂuenza virus infection. Contrasting with the ﬁndings of observa-
ional studies, ecological or modeling studies have demonstrated
ncreased risk of severe seasonal inﬂuenza disease in pregnancy
11]. Future research should conﬁrm the risk of severe seasonal
nﬂuenza disease in pregnancy seen in modeling studies and to rec-
ncile incongruities between the observational and the ecological
iterature.
Important data supporting WHO  recommendations that
regnant women be prioritized for inﬂuenza vaccine receipt came
rom the landmark Mother’s Gift trial in Bangladesh [1,12]. In this
rial, pregnant women were immunized with either pneumococcal
olysaccharide vaccine (PPV) or seasonal inﬂuenza vaccine. They
ere then followed for respiratory illness with fever, while their
ewborns were monitored for both respiratory illness with fever as
ell as laboratory-conﬁrmed inﬂuenza. Inﬂuenza vaccine receipt
as associated with a 36% reduction in respiratory illness with
ever among women and a 63% reduction in laboratory-conﬁrmed
nﬂuenza in their children [12]. This study was an important
roof of principle that paediatric respiratory infections can be pre-
ented through maternal immunization strategies in a low-income
etting. Limitations included a small sample size, lack of laboratory-
onﬁrmed outcomes in the women, use of an active comparator
accine active against respiratory infections, and inﬂuenza vaccine-
elated analyses were not pre-speciﬁed [13]. Encouraged by these
esults, the Bill & Melinda Gates Foundation (BMGF) invested in
hree large clinical efﬁcacy trials in Mali, Nepal, and South Africa
14]. The South Africa trial is the ﬁrst to be published, and it has con-
rmed the vaccine efﬁcacy ﬁndings of Mother’s Gift [15]. Among
IV-uninfected women and their offspring, attack rates for RT-
CR—conﬁrmed inﬂuenza in the placebo arm were both 3.6%, and
ttack rates in the vaccine arm were 1.8% and 1.9%, respectively.
mong HIV-uninfected women, inﬂuenza vaccine exposure was
ssociated with a 50% decrease in laboratory-conﬁrmed inﬂuenza
isease in pregnant women and a 49% decrease in laboratory con-
rmed inﬂuenza disease in their children <6 months. [15]. Given the
arity of severe inﬂuenza-associated outcomes, it may  not be fea-
ible for clinical trials to determine vaccine efﬁcacy against severe
nﬂuenza disease or to calculate precise baseline rates of severe
nﬂuenza disease among those exposed to placebo to inform dis-
ase burden estimates.
Another intriguing ﬁnding from the Mother’s Gift trial was
 difference in birth weight between intervention groups, with
nﬂuenza vaccine-exposed newborns having a signiﬁcantly higher
irth weight than PPV-exposed newborns among the subset of
hildren born during the inﬂuenza season [16]. Numerous obser-
ational studies have also found associations between vaccine
xposure and birth weight, as well as with additional beneﬁcial
irth outcomes including decreased small for gestational age (SGA)
nd preterm births [17]. In GAVI’s impact model, a sensitivity
nalysis estimated that the number of infant deaths averted by
aternal inﬂuenza immunization would increase from 170,000
ives to 900,000 lives over a 15 year program in GAVI-eligible
ountries if vaccine prevention of preterm birth was  included in3 (2015) 6376–6379 6377
the model [2]. However, the model assumed vaccine exposure pre-
vented 17% deaths from preterm complications [2], an estimate that
is likely overly optimistic [18]. In contrast to the Mother’s Gift trial,
the South Africa trial found no statistical difference in birth weight,
SGA, or preterm birth between vaccine- and placebo-exposed new-
borns [15].
The three BMGF clinical trials will provide valuable data about
vaccine efﬁcacy to prevent inﬂuenza disease in three low-resource
countries. Given the limitations of clinical trials to determine vac-
cine efﬁcacy against severe disease outcomes, observational studies
have been conducted or are being planned to estimate vaccine
effectiveness to prevent inﬂuenza hospitalizations [19,20]. These
observational data are valuable for policy makers; however, non-
clinical trial data should be interpreted with some caution. Twenty
years ago, there was  tremendous excitement in the inﬂuenza vac-
cine community about observational studies in the elderly that
found dramatic beneﬁts of vaccination against severe outcomes
[21]. Subsequently, these ﬁndings were discredited and attributed
to uncontrolled confounding in the observational study designs
[22].
Inﬂuenza vaccines have been used in pregnant women  for
decades, and there is a large knowledge base that supports that the
vaccines are safe to use in pregnancy. However, pregnant women
have been historically excluded from vaccine trials conducted for
licensure of new products, as pregnant women are often consid-
ered vulnerable due to physiologic changes during pregnancy and
are protected by additional regulations [23]. For this reason, there
has been few randomized, placebo-controlled vaccine trials con-
ducted with pregnant women. In 2014, the WHO  Global Advisory
Committee on Vaccine Safety (GACVS) published the outcome of
its expert review of inactivated inﬂuenza vaccine safety in preg-
nancy, reporting that it identiﬁed no safety signals among pregnant
women associated with inactivated inﬂuenza vaccine receipt [24].
Recent systematic reviews of vaccine safety studies support the
conclusions of GACVS that there is no increased risk of adverse
maternal, fetal, or newborn outcomes associated with maternal
inﬂuenza vaccination [25–27]. Of the three BMGF-sponsored ran-
domized clinical trials of inﬂuenza vaccine in pregnant women [14],
two include placebo control arms, facilitating vaccine safety eval-
uations.
From a policy-making perspective, the most important data gap
in the ﬁeld of maternal inﬂuenza immunization is the expected
impact a vaccine program would have on prevention of mortality
and severe disease. To determine anticipated deaths or severe ill-
nesses averted from a maternal inﬂuenza immunization strategy,
vaccine impact modeling requires severe inﬂuenza disease inci-
dence estimates in pregnant women and in children <6 months,
as well as estimates of vaccine effectiveness to prevent severe out-
comes. The lack of such estimates may  limit decisions about vaccine
introduction in many countries.
In 2013, SAGE acknowledged delays in development and imple-
mentation of maternal inﬂuenza immunization policies globally
and requested WHO  to address obstacles that prevent the devel-
opment of policies and national implementation efforts [23]. In
response, the WHO, jointly with partners, engaged in numer-
ous activities to support evidence-based inﬂuenza vaccine policy
making and implementation of maternal inﬂuenza immunization
programs in countries. The WHO  Initiative for Vaccine Research
(IVR) has a broad portfolio of activities relevant to maternal
inﬂuenza immunization encompassing three main areas of work:
(1) thorough evidence reviews of disease burden and vaccine per-
formance; (2) addressing global barriers to the implementation of
maternal immunization; and (3) developing implementation guid-
ance for maternal inﬂuenza immunization programs.
IVR is supporting a working group to evaluate inﬂuenza data to
inform vaccine impact and economic modeling which is reviewing
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nﬂuenza disease risk and morbidity in pregnant women, children
6 months of age, and the fetus, as well as vaccine performance
o reduce inﬂuenza disease in these groups. The working group
as four objectives: (1) to determine key parameters needed for
nﬂuenza vaccine impact and health economic modeling studies,
ith a focus on pregnant women and low-resource settings; (2)
o determine evidence-based assumptions for these key parame-
ers; (3) to evaluate the quality of existing data; and (4) to provide
ecommendations to WHO  for addressing data gaps. The working
roup leaders are conducting a series of relevant systematic litera-
ure reviews and the ﬁndings are presented to the working group
o obtain feedback on methodology, analysis, and interpretation. A
nal report of the working group is anticipated in late 2015.
Barriers to maternal immunization implementation are
ddressed by IVR through development of technical guidance
ssisting countries in introducing maternal inﬂuenza immu-
ization. WHO  is developing health economics guidance for the
valuation of economic burden of inﬂuenza disease, inﬂuenza
accine cost effectiveness, and a maternal inﬂuenza immunization
rogram costing tool. These tools will enable decision makers in
ow-resource setting to compare maternal inﬂuenza immunization
ith regards to other health interventions. WHO  is developing
ools to assess conﬁdence and use of vaccines among pregnant
omen. Along with the Tailoring Immunization Programmes for
nﬂuenza (TIP FLU) guide developed by WHO/Europe [28], these
ools can help countries to identify reasons for vaccine hesitancy
nd develop interventions to best address those speciﬁc issues.
ther implementation issues receiving WHO  attention include
eviewing information needs for pregnancy/lactation sections of
ackage inserts [29], developing adverse event following immu-
ization guidance for maternal immunization [30], and developing
trategies to support year-round availability of inﬂuenza vaccine
31].
As a next step, WHO  is synthesizing the various tools and guid-
nce for maternal immunization into an implementation guide for
est-practices delivery of inﬂuenza vaccine to pregnant women.
his implementation guide is being produced with the advice of
 group of global vaccine delivery experts, and will be adaptable
or country-speciﬁc needs as well as for future vaccines targeting
regnant women.
In April 2014, SAGE again reviewed maternal inﬂuenza immu-
ization. After reviewing ongoing efforts in the ﬁeld, SAGE
ncouraged WHO  to promote more implementation research to
ollect generalizable data on the best ways to integrate mater-
al immunization into routine antenatal care in low-resource
ettings [32]. Furthermore, SAGE emphasized the importance of
he maternal immunization platform, in general, and called upon
HO to afﬁrm its commitment to building the evidence base
o strengthen vaccine delivery during pregnancy, as it has great
otential for infection prevention in high-risk groups worldwide,
ven beyond inﬂuenza and tetanus. A meeting of global health
takeholders in maternal immunization organized by the Bill and
elinda Gates Foundation in January 2015 further identiﬁed the
eed for a stronger evidence base, including burden of disease,
aternal immunization efﬁcacy and safety for mother, fetus and
nfant, and for implementation research to assess healthcare costs,
ntegrated healthcare approaches in order to evaluate the invest-
ent case for manufacturers and donors, policy recommendations,
icensure, and vaccine uptake [8]. In March 2015, WHO  convened
he Technical Consultation on Maternal Inﬂuenza Immunization
nd Evidence to identify data gaps in need of further efforts to
trengthen uptake of maternal inﬂuenza immunization programs.
n the consultation, subject matter experts and global stakeholders
eviewed inﬂuenza disease burden, vaccine performance, vaccine
afety, program impact, and implementation issues. In recent
ears, major advancements have been made in the ﬁeld, and3 (2015) 6376–6379
several critical vaccine clinical trials and reviews of disease burden
will be published in 2015 and 2016 [7,33,34]. After review of the
relevant evidence, the consensus of participants recommended
further data collection on integration of vaccine programs into
antenatal care platforms in low-resource settings.
In order to inform widespread implementation of maternal
inﬂuenza immunization as a strategy, more work needs to be
done. In addition to the needed research to better character-
ize the risk and incidence of severe inﬂuenza disease and the
effectiveness of vaccine to prevent severe inﬂuenza disease, there
must be increased focus on ways to optimally deliver vaccines to
pregnant women in low-resource settings. Demonstration projects
are needed to evaluate different vaccine delivery approaches that
integrate into routine care delivery. Delivery methods that are cost
effective and do not adversely affect routine immunization pro-
grams or antenatal care must be identiﬁed. Post-licensure safety
surveillance must be implemented. Monitoring and evaluation sys-
tems are needed, including strategies to measure the number of
severe inﬂuenza illnesses reduced by any program. The goal of
any implementation research agenda should be to produce sus-
tainable, integrated programs with predictable vaccine supply and
manageable delivery, storage, and stock rotations procedures.
Since 2012, there have been many advances in the ﬁeld of
maternal inﬂuenza immunization, and more data are expected
soon. Many countries, mostly with low or middle income, have
not yet introduced this strategy into their national immunization
programs. Low-resource countries have multiple competing public
health priorities and limited resources. Additional data, particu-
larly regarding the incidence of severe inﬂuenza disease in pregnant
women and young children and the anticipated impact of mater-
nal inﬂuenza immunization, may  be necessary to demonstrate the
value proposition of maternal inﬂuenza immunization in countries
considering inﬂuenza vaccine policies.
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